Mercy BioAnalytics Secures FDA Approval for Pivotal Study of Ovarian Cancer Test

Mercy BioAnalytics Receives FDA Approval for Pivotal Study

Mercy BioAnalytics, a leader in early cancer detection technology, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting approval for the Investigational Device Exemption (IDE) concerning its Evident™ Ovarian Cancer Screening Test. This groundbreaking approval allows the company to advance its clinical validation study titled 'Safety in Ovarian Cancer for Average-Risk Women – Analysis' (SOARA), subject to successful review by the Institutional Review Board (IRB).

The SOARA clinical study is pivotal as it aims to evaluate the safety of the Evident test as a screening tool for ovarian cancer among average-risk women. This demographic frequently faces challenges with late-stage diagnoses, making the development of a reliable screening method crucial. Currently, there is no FDA-approved screening test for ovarian cancer, highlighting the importance of Mercy's initiative.

Dawn Mattoon, Ph.D., the Chief Executive Officer of Mercy BioAnalytics, expressed her enthusiasm, stating, "The FDA approval of our IDE application is a critical step in propelling the Evident Test through the regulatory approval process. Our SOARA study is designed to build prospective evidence supporting our test while we strive to make earlier ovarian cancer detection accessible to more women."

Ovarian cancer is notably one of the deadliest forms of gynecological cancer, often diagnosed at advanced stages when treatment options become limited. The development and approval of the Evident Ovarian Cancer Screening Test could change the landscape of ovarian cancer detection significantly. Previously, the FDA granted Breakthrough Device Designation to this innovative test, recognizing its potential to enhance patient outcomes through earlier diagnosis.

The Evident Ovarian Cancer Screening Test operates on Mercy's proprietary Mercy Halo™ liquid biopsy platform, which leverages biomarker colocalization to analyze blood-based extracellular vesicles that carry cancer-related signatures. This technology represents a significant advancement in the non-invasive detection of cancer, promising greater efficacy compared to traditional methods.

While the IDE approval facilitates the commencement of a detailed clinical investigation, it is important to note that it does not equate to full FDA clearance for the Evident Ovarian Cancer Screening Test. This distinction is critical as Mercy continues its journey towards obtaining regulatory approval.

The Mission of Mercy BioAnalytics

Mercy BioAnalytics aims to alleviate suffering and save lives through the early detection of cancers. Detecting cancers at earlier stages significantly increases the chances of successful treatment, making their innovations in liquid biopsy technologies pivotal. By focusing initially on ovarian and lung cancers, the company targets some of the harshest challenges within oncology, bringing hope and advanced solutions to patients and healthcare providers alike.

As the landscape of cancer detection evolves, Mercy BioAnalytics is at the forefront, dedicated to pushing scientific boundaries and striving for a future where early detection of cancer can lead to lifesaving interventions for thousands of women. Their commitment to this mission is evident in their relentless pursuit of innovative solutions to combat one of the leading causes of cancer mortality worldwide.